CVS (CVS) director Aguirre now holds 40,950 CVS shares after grant

Rhea-AI Filing Summary

CVS Health (CVS) director Fernando Aguirre reported the receipt of company stock as part of his regular board compensation. On 11/20/2025, he acquired 1,800 shares of CVS Health common stock at a price of $76.04 per share. This stock was issued as payment of a semi-annual retainer under the company’s 2017 Incentive Compensation Plan, meaning it represents routine director compensation rather than an open-market purchase. Following this grant, Aguirre beneficially owns 40,950 shares of CVS Health common stock, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider AGUIRRE FERNANDO

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,800	$76.04	$137K

Holdings After Transaction: Common Stock — 40,950 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AGUIRRE FERNANDO

(Last) (First) (Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET RI 02895

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		A		1,800(1)	A	$76.04	40,950	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.

	/s/ Fernando Aguirre	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CVS Health (CVS) disclose in this Form 4 filing?

The filing reports that director Fernando Aguirre received 1,800 shares of CVS Health common stock on 11/20/2025 as part of his board compensation.

At what price were the CVS Health shares issued to the director?

The 1,800 CVS Health shares were issued at a price of $76.04 per share, described as being issued at the market price.

Why did the CVS Health director receive these 1,800 shares?

The 1,800 shares of CVS Health common stock were issued in payment of a semi-annual retainer under the company’s 2017 Incentive Compensation Plan.

How many CVS Health shares does the director own after this transaction?

After the reported transaction, director Fernando Aguirre beneficially owns 40,950 shares of CVS Health common stock.

Is this CVS Health Form 4 transaction a market purchase or compensation grant?

The transaction is a compensation grant, with shares issued as a semi-annual retainer under the 2017 Incentive Compensation Plan, not an open-market purchase.

How is the director’s ownership in CVS Health classified after the grant?

The filing states that the 40,950 shares of CVS Health common stock are held with direct ownership.